Funding Support and Author Disclosures Dr Coca’s employer, Icahn School of Medicine at Mount Sinai, owns part of Renalytix; he has served as a consultant for Renalytix, Takeda, Nuwellis, Vifor, Bayer, Boehringer Ingelheim, Reprieve Cardiovascular, Axon, and 3ive; has ownership interest in Renalytix and pulseData; has received research funding from Renalytix, ProKidney, Renal Research Institute, and XORTX; has patents or royalties from Renalytix; has served in an advisory or leadership role for Renalytix and Reprieve Cardiovascular; is Associate Editor for Kidney360; and has served on the Editorial Boards of the Journal of the American Society of Nephrology, Clinical Journal of the American Society of Nephrology, and Kidney International.